Sustanon Deca Durabolin And Dianabol Cycle Stack And Dosages Train Your Mind To Build Your Body

Below is a concise, practical guide that explains what a typical **testosterone cycle** looks like in the context of medical treatment (e.g., hormone‑replacement therapy for men with low testosterone).
It does **not** provide instructions for illicit or performance‑enhancing use, and it is meant to be read as an educational overview.

---

## 1. Why a "cycle" is used

| Medical purpose | Typical dosing schedule |
|------------------|------------------------|
| **Hormone replacement therapy (HRT)** | Continuous daily or weekly dosing; no "off‑period." |
| **Short‑term experimental therapy** (e.g., to test effects of testosterone) | Periodic on/off cycles to assess response and safety. |

> In HRT the goal is steady-state levels, so a *true* cycle is rarely necessary.
> When research or certain therapeutic protocols use periodic dosing, they are called "cycles."

---

## 2. Common dosing forms

| Form | Typical dosage (per day/week) | Notes |
|------|------------------------------|-------|
| **Oral tablets** | 1–3 mg/day | Rapid absorption; first-pass metabolism may lower bioavailability. |
| **Transdermal patch** | 0.5–2 mg/day | Provides continuous release; avoid areas with cuts or excessive sweating. |
| **Topical gel** | 50 mg/spot twice daily | Absorption depends on skin area and condition. |
| **Injectable (intramuscular)** | 100–200 mg every 4–6 weeks | Longer-acting formulations available. |

The dosing schedule is usually adjusted based on therapeutic response, side‑effect profile, and laboratory monitoring of hormone levels.

---

## 3. Pharmacokinetics (PK)

| Parameter | Typical Range (Adults) |
|-----------|------------------------|
| **Absorption** | Oral: ~50–80 % bioavailability; parenteral: 100 % |
| **Distribution** | Volume of distribution ≈ 0.6–1 L/kg; highly protein‑bound (>95 %) mainly to albumin and α‑1‑acid glycoprotein |
| **Metabolism** | Primarily hepatic via CYP3A4 (phase I oxidation) → secondary metabolites conjugated by glucuronidation or sulfation |
| **Elimination Half‑life** | ~2–3 h after oral dosing; longer (~5–6 h) when given intravenously due to slower clearance |
| **Clearance** | 0.25–0.35 L/kg/h; renal excretion minimal (